{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.9","upperLimit":"1010","value":"161"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.","dispersionType":"Full Range","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib )"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic analysis set (PAS): All participants to whom study treatment has been assigned by randomization to asciminib and that had a valid trough plasma concentration taken at week 48.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Trough Plasma Concentrations.","type":"SECONDARY","unitOfMeasure":"ng/mL"}